Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
1 - 25 out of 159Page size: 25
Sort by: 1st author
  1. Published

    First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

    Abdul Razak, A. R., Mau-Sørensen, M., Gabrail, N. Y., Gerecitano, J. F., Shields, A. F., Unger, T. J., Saint-Martin, J. R., Carlson, R., Landesman, Y., McCauley, D., Rashal, T., Lassen, Ulrik Niels, Kim, R., Stayner, L., Mirza, M. R., Kauffman, M., Shacham, S. & Mahipal, A., Dec 2016, In: Journal of Clinical Oncology. 34, 34, p. 4142-4150 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Application of cell-free DNA for genomic tumor profiling: a feasibility study

    Ahlborn, L. B., Rohrberg, K. S., Gabrielaite, M., Tuxen, I. V., Yde, C. W., Spanggaard, I., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Mau-Sorensen, M. & Østrup, O., Feb 2019, In: OncoTarget. 10, 14, p. 1388-1398

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Concordance of mutation detection in circulating tumor DNA in early clinical trials using different blood collection protocols

    Ahlborn, L. B., Madsen, M., Jonson, L., Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W. & Mau-Sorensen, M., 2017, In: Clinical Laboratory. 63, 10, p. 1755-1759

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Ahlborn, L. B., Tuxen, I. V., Mouliere, F., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W., Oestrup, O. & Mau-Sorensen, M., 2018, In: OncoTarget. 9, 66, p. 32570-32579

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2

    Alanin, M. C., Klausen, C., Cayé-Thomasen, Per, Thomsen, C., Fugleholm, K., Poulsgaard, L., Lassen, Ulrik Niels, Mau-Sorensen, M. & Hofland, K. F., Dec 2015, In: European Archives of Oto-Rhino-Laryngology. 272, 12, p. 3627-3633 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2: a retrospective case series

    Alanin, M. C., Klausen, C., Cayé-Thomasen, Per, Thomsen, C., Fugleholm, Kåre, Poulsgaard, L., Lassen, Ulrik Niels, Mau-Sørensen, M. & Hofland, K. F., 2016, In: International Journal of Neuroscience. 126, 11, p. 1002-6 5 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    A prospective PET study of patients with glioblastoma multiforme

    Andersen, P. B., Blinkenberg, M., Lassen, Ulrik Niels, Kosteljanetz, M., Wagner, A., Poulsen, H. S., Sørensen, Per Soelberg & Paulson, Olaf B., Jun 2006, In: Acta Neurologica Scandinavica. 113, 6, p. 412-8 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome

    Araujo B de Lima, V., Borch, A., Hansen, M., Draghi, A., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, Apr 2020, In: Cytotherapy. 22, 4, p. 204-213 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

    Araujo B. de Lima, V., Hansen, M., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, 25 Mar 2021, In: Frontiers in Oncology. 11, 11 p., 558248.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Bang-Christensen, S. R., Pedersen, R. S., Pereira, M. A., Clausen, T. M., Løppke, C., Sand, N. T., Ahrens, T. D., Jørgensen, A. M., Lim, Y. C., Goksøyr, L., Choudhary, S., Gustavsson, T., Dagil, R., Daugaard, M., Sander, A. F., Torp, M. H., Søgaard, M., Theander, T. G., Østrup, O., Lassen, U. & 3 others, Hamerlik, P., Salanti, Ali & Agerbæk, Mette Ørskov, 2019, In: Cells. 8, 9, 21 p., 998.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    New pathogenic germline variants identified in mesothelioma

    Belcaid, L., Bertelsen, B., Wadt, Karin Anna Wallentin, Tuxen, I., Spanggaard, I., Højgaard, M., Sørensen, Jens Benn, Ravn, J., Lassen, Ulrik Niels, Nielsen, Finn Cilius, Rohrberg, K. & Westmose Yde, C., 2023, In: Lung Cancer. 179, 8 p., 107172.

    Research output: Contribution to journal › Review › Research › peer-review

  12. Published

    High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

    Bertelsen, B., Tuxen, I. V., Yde, C. W., Gabrielaite, M., Torp, M. H., Kinalis, S., Oestrup, O., Rohrberg, K., Spangaard, I., Santoni Rugiu, Eric, Wadt, Karin Anna Wallentin, Mau-Sorensen, M., Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2019, In: npj Genomic Medicine. 4, 1, 11 p., 13.

    Research output: Contribution to journal › Journal article › Research › peer-review

  13. Published

    Putting data to work for precision medicine

    Bjerrum, A. & Lassen, Ulrik Niels, 2023, In: Cell Reports Medicine. 4, 7, 3 p., 101090.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  14. Published

    Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

    Bono, P., Massard, C., Peltola, K. J., Azaro, A., Italiano, A., Kristeleit, R. S., Curigliano, G., Lassen, Ulrik Niels, Arkenau, H. T., Hakulinen, P., Garratt, C., Ikonen, T., Mustonen, M. V. J. & Rodon, J. A., 2020, In: ESMO Open. 5, 6, 11 p., e001081.

    Research output: Contribution to journal › Journal article › Research › peer-review

  15. Published

    Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

    Borch, A., Bjerregaard, A. M., Araujo Barbosa de Lima, V., Østrup, O., Yde, C. W., Eklund, A. C., Mau-Sørensen, M., Barra, C., Svane, Inge Marie, Nielsen, Finn Cilius, Funt, S. A., Lassen, Ulrik Niels & Hadrup, S. R., 2023, In: Frontiers in Genetics. 14, 13 p., 1058605.

    Research output: Contribution to journal › Journal article › Research › peer-review

  16. Published

    Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

    Borghaei, H., Alpaugh, K., Hedlund, G., Forsberg, G., Langer, C., Rogatko, A., Hawkins, R., Dueland, S., Lassen, Ulrik Niels & Cohen, R. B., 2009, In: Journal of Clinical Oncology. 27, 25, p. 4116-23 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  17. Published

    Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study

    Briggs, A., Paracha, N., Rosettie, K., Upton, A., Bokemeyer, C., Lassen, Ulrik Niels & Sullivan, S. D., Jan 2022, In: Oncology. 100, 2, p. 124–129 6 p.

    Research output: Contribution to journal › Letter › Research › peer-review

  18. Published

    Changes in key recruitment performance metrics from 2008-2019 in industrysponsored phase III clinical trials registered at ClinicalTrials.gov

    Brøgger-Mikkelsen, Mette, Zibert, J. R., Andersen, A. D., Lassen, Ulrik Niels, Hædersdal, Merete, Ali, Z. & Thomsen, Simon Francis, 2022, In: PLoS ONE. 17, 7 July, p. 1-15 e0271819.

    Research output: Contribution to journal › Journal article › Research › peer-review

  19. Published

    Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer

    Carlson, J. J., Italiano, A., Brose, M. S., Federman, N., Lassen, Ulrik Niels, Kummar, S. & Sullivan, S. D., 2022, In: American Journal of Managed Care. 28, p. S26-S32

    Research output: Contribution to journal › Journal article › Research › peer-review

  20. Published

    A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

    Cejalvo, J. M., Jacob, W., Fleitas Kanonnikoff, T., Felip, E., Navarro Mendivil, A., Martinez Garcia, M., Taus Garcia, A., Leighl, N., Lassen, Ulrik Niels, Mau-Soerensen, M., Adessi, C., Michielin, F., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2019, In: ESMO Open. 4, 4, 7 p., e000532.

    Research output: Contribution to journal › Journal article › Research › peer-review

  21. Published

    The role of nuclear medicine in the diagnosis of cancer of unknown origin

    Demir, H., Berk, F., Raderer, M., Plowman, P. N., Lassen, Ulrik Niels, Daugaard, G., Clausen, M., Bohuslavizki, K. H., Peters, M., Harmer, C., Malamitsi, J. & Aktolun, C., Jun 2004, In: American Journal of Nuclear Medicine and Molecular Imaging. 48, 2, p. 164-73 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  22. Published

    First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors

    Dienstmann, R., Lassen, Ulrik Niels, Cebon, J., Desai, J., Brown, M. P., Evers, S., Su, F., Zhang, W., Boisserie, F., Lestini, B., Schostack, K., Meresse, V. & Tabernero, J., Apr 2016, In: Targeted Oncology. 11, 2, p. 149-56 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  23. Published

    Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer

    Dizon, D. S., Damstrup, L., Finkler, N. J., Lassen, Ulrik Niels, Celano, P., Glasspool, R., Crowley, E., Lichenstein, H. S., Knoblach, P. & Penson, R. T., Jul 2012, In: International Journal of Gynecological Cancer. 22, 6, p. 979-86 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  24. Published

    Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, 2019, In: Trials. 20, 12 p., 708.

    Research output: Contribution to journal › Journal article › Research › peer-review

  25. Published

    Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, Jul 2017, In: B M J Open. 7, 7, 10 p., e015579.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 4 5 6 7 Next

ID: 4952653